|
|
Blood, Vol. 107, Issue 2, 550-557, January 15, 2006
Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice
Blood Malik et al.
107: 550
Supplemental materials for: Malik et al
Files in this Data Supplement:
- Figure S1. Potency of G6-23-IgG and mFlt(1-3)-IgG interfering with VEGF-stimulated endothelial cell proliferation (PDF, 58.9 KB) -
Human microvascular endothelial cells were grown in a basal medium containing 30 ng/mL of murine VEGF and the indicated amounts of G6-23-IgG or mFlt(1-3)-IgG. Data represent mean standard error of the mean (n=3). Lines with open or closed circles represent total cell numbers in the presence of G6-23-IgG and mFlt(1-3)-IgG, respectively. Basal conditions contained 0.5 % fetal bovine serum, media containing 10% fetal bovine serum was added as a positive control. Cells were harvested after 5 days of incubation, with each data point representing the mean of triplicate samples ± standard deviation. Data shown are from 1 representative of 2 independent experiments.
- Figure S2. Effect of G6-23-IgG or mFlt(1-3)-IgG on postnatal body growth, organ weight, and survival of neonatal CD1 mice (PDF, 44.9 KB) -
(A) Ten neonatal mice per group were treated with G6-23-IgG or isotype matched control antibody at a dose of 10mg/kg or 25 mg/kg, IP, respectively. PBS was used as vehicle control. Body weights were assessed daily. Data represent mean ± standard deviation. (B) Kaplan Meier survival curves of CD1 neonatal mice treated as described in A. Both concentrations induced a similar decrease in survival, suggesting maximal pharmacological activity of G6-23 at the 10mg/kg dose regimen. (C) Ten neonatal mice per group were treated with mFlt-(1-3)-IgG or isotype matched control antibody at a dose of 25 mg/kg or 50 mg/kg, IP, respectively. PBS was used as vehicle control. Body weights were assessed daily. Data represent mean ± standard deviation. (D) Kaplan Meier survival curves of CD1 neonatal mice treated as explained in C. Both concentrations induced a similar decrease in survival, suggesting maximal pharmacological activity of Flt-IgG at the 25bmg/kg dose regimen.
|
|
